Gaucher's disease is caused by a deficiency of the lysosomal enzyme glucocerebrosidase (glucosylceramidase;
A deficiency of this enzyme results in the accumulation of glucocerebroside, the characteristic feature of Gaucher's disease. Lysosomal storage disorders, such as Gaucher's disease, have been prime targets for enzyme replacement therapy, the administration of exogenous enzyme in an effort to hydrolyze the stored material. Earlier reports of enzyme replacement in Gaucher's disease have been encouraging (1, 2) but this therapy has depended upon enzyme partially purified by a laborious method that provides a very low yield of enzyme (3) . A relatively rapid, high-yield method for the purification of glucocerebrosidase is essential to investigation and implementation of enzyme replacement therapy.
The purification of glucocerebrosidase has been hindered by the fact that the enzyme is tightly membrane-bound and requires detergent to be solubilized. This problem has been resolved by the use of organic solvent precipitation to produce a detergent-free, soluble enzyme (4) . We now describe the preparation, in high yield, of human glucocerebrosidase. Purification was carried out by monitoring the acid ,3-glucosidase activity, which appears, for the most part, to be identical to glucocerebrosidase (5) . Direct assay of the purified preparation provided verification that it was a highly active glucocerebrosidase. The enzyme has been infused into a patient with Gaucher's disease without any untoward effects. (Sepharose 4B) . Fifty milliliters of agarose was washed extensively with water and suspended in a total volume of 100 ml. One hundred milliliters of 2 M Na2CO3 and 20 g of CNBr dissolved in 10 ml of acetonitrile were added. The suspension was stirred for 2 min with a glass rod and the gel was then washed on a sintered glass funnel with 200 ml of 00 0.5 M NaCl, 0.2 M NaHCO3 at pH 9.0, and 200 ml of 00 water. After all excess water had been removed by vacuum suction the moist cake was added to 50 ml of 1 mM PS, 0.2% sodium dodecyl sulfate, 0.5 M NaCl, 0.2 M NaHCO3, pH 9 .0. After this suspension had been rotated for 2 hr at room temperature, 50 ml of 2 M ethanolamine, pH 9.0, was added to inactivate any sites on the gel that had not reacted with PS. After 45 min the gel was washed extensively with water.
MATERIALS
This synthetic procedure normally couples approximately 40 nmol of PS to each ml of agarose, as measured by acid hydrolysis and amino acid analysis (9) . Since this degree of substitution was too high for use in the purification method, the PS-agarose was diluted with sufficient unreacted agarose to 4672 Abbreviations: PS, phosphatidylserine; Con A, concanavalin A. provide a concentration of approximately 20 nmol of PS per ml of agarose.* Purification. All purification steps were carried out at 40 unless otherwise stated. Frozen human placenta obtained from a local hospital was stripped of membranes and homogenized in water (25% wt/vol) for 10 min at top speed in a Sorvall Omnimixer. The homogenate was centrifuged at 10,000 X g for 20 min, and the supernatant was discarded. The pellet was homogenized (40% wt/vol) at top speed in a Sorvall Omnimixer for 60 sec at 00 in 50 mM sodium chloride, 50 mM sodium citrate, at pH 6.0, with 0.02% sodium azide (Buffer A) containing 1% taurocholic acid. After centrifugation at 10,000 X g for 20 min, 2200 ml of the taurocholate supernatant, containing most of the f3-glucosidase activity, was adjusted to pH 5.0 with dilute acetic acid, and 194 mg of solid ammonium sulfate was added per ml of solution to give 35% saturation. The suspension was centrifuged at 10,800 X g for 20 min and the pellet was discarded. The supernatant was adjusted to pH 6.0 with dilute NaOH and then taken to 55% ammonium sulfate per milliliter of original solution. After centrifuging at 10,800 X g for 20 min, the supernatant was discarded, and the pellet was dissolved in 900 ml of Buffer A containing 0.5% taurocholate.
Fifty milliliters of Con-A-Sepharose was poured into a 2.5 cm diameter column at room temperature and equilibrated with Buffer A containing 0.5% taurocholate, 5 mM MnCl2, and 5 mM CaC12. Three hundred milliliters of the ammonium sulfate fraction was made 5 mM in both MnCl2 and CaCl2 and applied to the Con-A-Sepharose column at room temperature. The column was washed with 500 ml of Buffer A containing 0.5% taurocholate and 0.1 M a-methyl-mannoside. The eluate was concentrated to approximately 250 ml over an Amicon XM-50 membrane.
Ten volumes of absolute ethanol per volume of protein solution was magnetically stirred and was cooled to -15°. The Con-A-Sepharose eluate was dripped into the rapidly stirring ethanol at a rate of 1 ml/min. The precipitate was collected by centrifugation at 2300 X g for 20 min at -10°and the supernatant was discarded. The pellet was dissolved in approximately 200 ml of Buffer A and dialyzed two times against the same buffer. The preparation was concentrated to approximately 150 ml over an Amicon PM-30 membrane.
A 2.5 X 7.5 cm column of PS-agarose was equilibrated at 40 with Buffer A. The concentrated enzyme preparation was added at a flow rate of 1 ml/min. After sample application, the column was washed with 250 ml of Buffer A and then with 50 ml of 0.5 M NaCI, 50 mM Na citrate, pH 6.0. The enzyme was eluted with 250 ml of 1.0 M NaCl, 40% (vol/vol) ethylene glycol, 1 mM 2-mercaptoethanol, 50 mM Na citrate, pH 6.0 (Fig. 1) .
The active fractions of the PS-agarose column, comprising approximately 60 ml, were combined and were made 5 mM in 2-mercaptoethanol. This solution was then concentrated very rapidly over a PM-10 membrane, first in a large 400 ml Amicon concentrator and then in a small 10 ml Amicon concentrator. When the f3-glucosidase had been concentrated to 1 ml, 4 ml of Buffer A was added and the solution was quickly concentrated again to 1 ml. The 1 ml was dialyzed against 250 ml of Buffer A with 1 mM 2-mercaptoethanol.
RESULTS AND DISCUSSION The purification of human placental ,B-glucosidase is summa-* The dilution of a substituted Sepharose gel with unsubstituted Sepharose has an effect that is similar, although not identical, to synthesis of substituted Sepharose with a lower ligand concentration (10) . fi-glucosidase activity is given in milliunits/mi. Fractions are approximately 15 ml; elution was begun at fraction 27. rized in Table 1 . Although the overall yield is 60%, this represents a modest exaggeration of the true yield; some increase in activity results from the fact that the pH optimum of glucocerebrosidase shifts from 5 to 6 during purification and all assays are performed at pH 6. The purification was monitored using the artificial substrate 4-methylumbelliferyl-1F-D-glucopyranoside. The purified m-glucosidase preparation was assayed for glucocerebrosidase activity, and 1000 nmol of glucocerebroside were hydrolyzed per mm5/mg of protein.
PS-Agarose chromatography ( Fig. 1) far-advanced Gaucher's disease. For the first administration, the enzyme was entrapped in resealed red blood cells as suggested by Ihler et al. (12) . Ten milliliters of the patient's own packed erythrocytes were mixed with 590 milliunits of enzyme in Buffer A in a sterile dialysis bag. The mixture was dialyzed for 2 hr at 40 against 1200 ml of 5 mM K2HIPO4/KH2PO4 at pH 7.4. The dialysis solution was then changed to 500 ml of 0.154 M NaCI, 5 mM K2HPO4/KH2PO4 at pH 7.4 and dialysis was continued for 2 hr at room temperature. After washing, 6 ml of resealed cells containing a total of 96 milliunits of 3-glucosidase were injected intravenously into the patient. The procedure was repeated on a larger scale 2 days later; an additional 435 milliunits of enzyme was entrapped in erythrocytes and administered to the patient. Three months later a total of 3700 milliunits of purified f3-glucosidase (step V, Table 1 ) was injected directly intravenously into the same patient on 2 successive days. No pyrexia, hypotension, change in heart rate, or effect on coagulation factors was observed following any of the injections. A complete description of the replacement trials is in preparation.
For trials of enzyme replacement therapy of Gaucher's disease to be properly conducted, supply of active nontoxic enzyme must not be a limiting factor. The development of a rapid high-yield purification procedure for glucocerebrosidase has been an essential step in implementing such trials.
